The Mayo Clinic has introduced a novel approach utilizing milk-derived nanoparticles aimed at targeting cholangiocarcinoma, a rare and aggressive bile duct cancer.
These nanoparticles are designed to improve the precision of therapeutic delivery, addressing a significant challenge in treating this cancer type, which currently has limited options.
This development could reshape treatment protocols, enhancing the effectiveness of existing therapies and potentially leading to better patient outcomes.